CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04450732
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:39:26.254037+00:00
- Published At
- 2023-12-05T00:00:00+00:00
- Record Updated At
- 2023-12-05
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["HER2-positive Breast Cancer", "HER2-positive Biliary Tract Cancer", "HER2-Positive Salivary Gland Carcinomas", "HER2-Positive Advanced Solid Tumor"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-12-05"- protocolSection.identificationModule.nctId
"NCT04450732"- protocolSection.identificationModule.officialTitle
"A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors"- protocolSection.statusModule.overallStatus
"UNKNOWN"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.